[Objective] This study aimed to investigate the combination effects of ligustrazine and cis-dichlorodiamine platinum （DDP） on anti-proliferation, cell cycle and apoptosis of SGC-7901 cell lines in vitro. [Methed] SG...[Objective] This study aimed to investigate the combination effects of ligustrazine and cis-dichlorodiamine platinum （DDP） on anti-proliferation, cell cycle and apoptosis of SGC-7901 cell lines in vitro. [Methed] SGC-7901 cells were treat- ed with ligustrazine and DDP alone or combined for 48 h for morphology assay. Anti-proliferative effects with the same treatment for 24, 48 and 72 h were assayed by MTT method, respectively. Cell cycle distribution and apoptosis assay of treated cells were performed in flow cytometry. Zhengjun Jin＇s protocol was used to assay the effect of drug combination. [Result] Ligustrazine significantly increased the prolif- eration inhibition rate of DDP on SGC-7901 cells in combination with DDP, com- paring with the effects of ligustrazine or DDP alone, and exhibited synergistic antitu- mor effect. The combination drug treatment induced cell cycle arrest occurred in S and G2 phase of the cell cycle and increased the apoptosis rate significantly. [Conclusion] Our results indicate that ligustrazine, as a low-toxic and natural herbal component, can significantly increase the anti-proliferative effect and apoptosis rate of antitumor drug DDP on human gastric carcinoma SGC：.-7901 cells.展开更多
[Objective] This study aimed to investigate the mechanism of apoptosis induced by ligustrazine(TMP) and cis-dichlorodiamine platinum(DDP) in SGC-7901 cell lines in vitro. [Methods] SGC-7901 cell lines were treated wit...[Objective] This study aimed to investigate the mechanism of apoptosis induced by ligustrazine(TMP) and cis-dichlorodiamine platinum(DDP) in SGC-7901 cell lines in vitro. [Methods] SGC-7901 cell lines were treated with ligustrazine and DDP alone or combined for 48 h for Western blot analysis, respectively. Western blot analysis was used to determine the expression of proteins involved in apoptosis including NF-κB p65, bax and caspase-3. [Results] The viability of SGC-7901 cells was inhibited after treated with ligustrazine and/or combined with DDP. The expression of NF-κB P65 protein decreased after treated with drugs, in which the protein decreased significantly in 1.2 mg/ml of TMP combined with 2 μg/ml of DDP group.Meanwhile, we investigated the protein expression of bax and caspase-3. The results showed that the expression of the two proteins increased following with the increasing concentration of TMP. [Conclusion] All the results indicated that ligustrazine combined with DDP could induce the apoptosis of SGC-7901 cell lines, and NF-κB maybe the possible way to induce the cell apoptosis.展开更多
目的检测内质网应激ATF6-CHOP通路的激活水平,以探究单宁酸(TA)联合顺铂(CDDP)抗肝癌的分子机制。方法用180μmol/L TA、0.9μg/m L CDDP单独用药或者联合用药处理肝癌Hep G2细胞24和48 h后,利用实时荧光定量PCR(q-RT-PCR)、蛋白免疫印...目的检测内质网应激ATF6-CHOP通路的激活水平,以探究单宁酸(TA)联合顺铂(CDDP)抗肝癌的分子机制。方法用180μmol/L TA、0.9μg/m L CDDP单独用药或者联合用药处理肝癌Hep G2细胞24和48 h后,利用实时荧光定量PCR(q-RT-PCR)、蛋白免疫印迹(Western Blot)技术检测细胞ATF6(ATF6α)、ATF6B(ATF6β)和CHOP的表达水平。结果药物处理24和48 h后,与对照组相比,TA组、CD-DP组和联合用药组ATF6 m RNA和蛋白水平、ATF6B蛋白水平、CHOP m RNA和蛋白水平均显著升高(P<0.01或P<0.05)。结论 TA能够联合CDDP增强肝癌Hep G2细胞内质网应激ATF6-CHOP通路的激活水平,ATF6-CHOP通路可能是TA和CDDP协同抗肝癌的分子机制之一。展开更多
基金Supported by the Fund for Excellent Young Teachers by Education Department of Henan(2010DDJS-224)Natural Science Fund of Education Department of Henan(2010C320001)
文摘[Objective] This study aimed to investigate the combination effects of ligustrazine and cis-dichlorodiamine platinum （DDP） on anti-proliferation, cell cycle and apoptosis of SGC-7901 cell lines in vitro. [Methed] SGC-7901 cells were treat- ed with ligustrazine and DDP alone or combined for 48 h for morphology assay. Anti-proliferative effects with the same treatment for 24, 48 and 72 h were assayed by MTT method, respectively. Cell cycle distribution and apoptosis assay of treated cells were performed in flow cytometry. Zhengjun Jin＇s protocol was used to assay the effect of drug combination. [Result] Ligustrazine significantly increased the prolif- eration inhibition rate of DDP on SGC-7901 cells in combination with DDP, com- paring with the effects of ligustrazine or DDP alone, and exhibited synergistic antitu- mor effect. The combination drug treatment induced cell cycle arrest occurred in S and G2 phase of the cell cycle and increased the apoptosis rate significantly. [Conclusion] Our results indicate that ligustrazine, as a low-toxic and natural herbal component, can significantly increase the anti-proliferative effect and apoptosis rate of antitumor drug DDP on human gastric carcinoma SGC：.-7901 cells.
基金Supported by the Fund for Excellent Young Teachers by Education Department of Henan(2010GGJS-224)
文摘[Objective] This study aimed to investigate the mechanism of apoptosis induced by ligustrazine(TMP) and cis-dichlorodiamine platinum(DDP) in SGC-7901 cell lines in vitro. [Methods] SGC-7901 cell lines were treated with ligustrazine and DDP alone or combined for 48 h for Western blot analysis, respectively. Western blot analysis was used to determine the expression of proteins involved in apoptosis including NF-κB p65, bax and caspase-3. [Results] The viability of SGC-7901 cells was inhibited after treated with ligustrazine and/or combined with DDP. The expression of NF-κB P65 protein decreased after treated with drugs, in which the protein decreased significantly in 1.2 mg/ml of TMP combined with 2 μg/ml of DDP group.Meanwhile, we investigated the protein expression of bax and caspase-3. The results showed that the expression of the two proteins increased following with the increasing concentration of TMP. [Conclusion] All the results indicated that ligustrazine combined with DDP could induce the apoptosis of SGC-7901 cell lines, and NF-κB maybe the possible way to induce the cell apoptosis.
文摘目的检测内质网应激ATF6-CHOP通路的激活水平,以探究单宁酸(TA)联合顺铂(CDDP)抗肝癌的分子机制。方法用180μmol/L TA、0.9μg/m L CDDP单独用药或者联合用药处理肝癌Hep G2细胞24和48 h后,利用实时荧光定量PCR(q-RT-PCR)、蛋白免疫印迹(Western Blot)技术检测细胞ATF6(ATF6α)、ATF6B(ATF6β)和CHOP的表达水平。结果药物处理24和48 h后,与对照组相比,TA组、CD-DP组和联合用药组ATF6 m RNA和蛋白水平、ATF6B蛋白水平、CHOP m RNA和蛋白水平均显著升高(P<0.01或P<0.05)。结论 TA能够联合CDDP增强肝癌Hep G2细胞内质网应激ATF6-CHOP通路的激活水平,ATF6-CHOP通路可能是TA和CDDP协同抗肝癌的分子机制之一。
